ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)

Terry Moore1, Austin Dalrymple 2, Lance Feller 3 and Paul Tuttle 4, 1ST. LouisUniv12651729, St. Louis, Missouri, 2Saint Louis University School of Medicine, Saint Louis, Missouri, 3Orlando, Florida, 4OSMS, Hobart, Wisconsin

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Biomarkers, JIA

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: JIA is a heterogeneous group of patients with varying types of biomarkers detected in a small percentage of patients. More specific biomarkers would help in diagnosis and lead to possible different  therapeutic regimens. Anti-cyclic citrulinated peptide antibodies (∝-CCP) may play a role in the inflammatory process in JIA. ∝-CCP antibodies have been detected in JIA patients with more severe disease. Other chemical reactions other than citrullination have also been detected, such as carbamylation, which has also shown to produce auto-antibodies (∝- carbamylated proteins (∝-CarP antibodies)). These, also, may play a part in the inflammatory process.  Also, 14-3-3η (eTa) proteins, which are chaperonins found in all eukaryotic cells, have been implicated as having diagnostic potential in inflammatory arthritides.

Methods: ∝-CCP isotypic antibodies ,∝-CarP antibodies, and eTa proteins were assayed  by ELISA in 29-47 rheumatoid factor (RF) + and 29-37 RF – polyarticular JIA patients, 34-42 oligoarticular, and 12-20 systemic-onset JIA patients depending on the assay.

Results: At least one ∝-CCP antibody isotype was detected in 60% of JIA patients ( IgA in 38%, IgM in 36%, and IgG in 24%). JIA patients that had all 3 isotypes were found to have more aggressive disease. These isotypes further evaluated showed multiple citrullinated epitopes including antibodies to citrullinated fibrinogen, alpha-enolase,  citrullinated vimentin, and citrullinated type II collagen. ∝-CarP antibodies were detected in only 20%, predominately in oligoarticular-onset JIA (31%) patients.  eTa proteins were detected in 30% of polyarticular RF+/RF- JIA patients and were associated with erosive disease. eTa proteins presence also may be a forerunner of +RF development.

Conclusion: Minor biomarkers, such as ∝-CCP antibodies, ∝-CarP antibodies, and eTa proteins may be found in a small percentage of JIA patients. Their presence, however, if detected may indicate a more aggressive disease, which may evolve into a polyarticular, erosive disease.. The possible use of hydroxychloroquine in these patients may help stabilize the disease in these patients.


Disclosure: T. Moore, None; A. Dalrymple, None; L. Feller, None; P. Tuttle, None.

To cite this abstract in AMA style:

Moore T, Dalrymple A, Feller L, Tuttle P. Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/minor-biomarkers-in-juvenile-idiopathic-arthritis-jia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/minor-biomarkers-in-juvenile-idiopathic-arthritis-jia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology